Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
2.03Last Year’s EPS
2.38Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: -12.48%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
While DaVita Inc. showed strong financial performance and pursued strategic growth initiatives such as the Latin America expansion and transitioning oral drugs, challenges with volume growth, disruptions caused by Hurricane Helene, and international income declines present significant concerns. The sentiment is balanced with achievements in certain areas and setbacks in others.Company Guidance
During the call, DaVita Inc. provided guidance for 2025, highlighting a projected adjusted operating income (OI) growth of 5.2% and adjusted earnings per share (EPS) growth of 11%. The guidance assumes flat treatment volume growth compared to 2024, with an anticipated revenue per treatment increase of 4.5% to 5.5%, driven partly by the inclusion of oral phosphate binders. Patient care costs are expected to rise by 6% to 7%, influenced by both the addition of oral medications and inflationary pressures. The company aims to maintain its capital allocation strategy, targeting leverage between three and 3.5 times EBITDA, and plans to return excess capital to shareholders through share repurchases. Free cash flow for 2025 is estimated to be between $1 billion and $1.25 billion. DaVita continues to pursue operational excellence and growth in integrated kidney care, with a focus on improving health outcomes and managing costs effectively.Strong Financial Performance
DaVita Inc. ended 2024 with adjusted operating income of $1.98 billion and adjusted EPS of $9.68, showing a year-over-year growth of 21% and 26% respectively. Free cash flow for the year was $1.16 billion.
Expansion in Latin America
Closed on three of the four acquisitions in Latin America, with the expansion in Brazil expected to close midyear 2025.
Oral Drugs Transition
Effective January 1, 2025, oral drugs transitioned from Medicare drug benefit to the dialysis benefit, potentially contributing $0 to $50 million in operating income.
Share Repurchase Program
Committed to returning capital to shareholders through share repurchases.
---
DVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $177.06 | $157.42 | -11.09% |
| Oct 29, 2024 | $158.31 | $141.22 | -10.80% |
| Aug 06, 2024 | $136.99 | $133.98 | -2.20% |
| May 02, 2024 | $142.24 | $134.45 | -5.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does DaVita (DVA) report earnings?
DaVita (DVA) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is DaVita (DVA) earnings time?
DaVita (DVA) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DVA EPS forecast?
DVA EPS forecast for the fiscal quarter 2025 (Q1) is 2.03.
---
